Li Lilly Bets Nearly 500m On Metabolic Disease Pact With Nimbus News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases

Peter tumminoMichael vi gettyJeb keiperEli lillyMichael viRuth gimenoNimbus therapeuticPfizer venturesNimbus chief executive officer jeb keiperLi lilly bets nearly 500m on metabolic disease pact with nimbus